Could steroids slash death rates from a rare pneumonia?

NCT ID NCT07152613

Not yet recruiting Disease control Sponsor: Qingyuan Zhan Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding corticosteroids (low or moderate dose) to standard care can reduce deaths from severe Pneumocystis pneumonia (PJP) in non-HIV patients in the ICU. PJP has a very high death rate of 60-80% in this group. The trial will compare two steroid doses against a placebo in 240 adults to find the safest and most effective approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Methylprednisolone (a corticosteroid)

What this could lead to

If successful, this could provide a clear dosing strategy for corticosteroids to lower the high death rate (60-80%) from severe PJP pneumonia in non-HIV patients.

What could go wrong

This is an early-stage trial with only 240 participants, so results may not apply to all patients. Corticosteroids can also increase infection risk or other side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCYSTIS JIROVECI PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Community-Acquired Pneumonia pneumocystosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCYSTIS JIROVECI PNEUMONIA